Crizanlizumab
ASH sickle cell disease research priorities address pain, organ dysfunction, drug development
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.
‘Discouraging’ results show stroke incidence rising among people with sickle cell disease
Stroke rates among individuals with sickle cell disease have increased steadily over the last 25 years despite guidelines aimed at prevention, according to results of a retrospective study.
Patients with sickle cell disease using disease-modifying therapies more, but not enough
Nearly three-quarters of individuals with sickle cell disease are not using disease-modifying therapies in their treatment, according to a study published in JAMA Network Open.
Life expectancy for people with sickle cell disease increases by a decade
Life expectancy for individuals with sickle cell disease has increased by a decade since 2008, according to a study conducted by Epic Research.
Crizanlizumab fails to reduce organ support-free days for inpatients with COVID-19
Crizanlizumab did not reduce organ support-free days or in-hospital mortality among patients hospitalized with moderate to severe COVID-19, according to study results presented at International Society on Thrombosis and Hemostasis Congress.
People with sickle cell disease seldom receive newer pain medications
Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.
VIDEO: Dosing evaluation trial aims to ‘broaden the label’ for sickle cell treatment
In this video, Matthew M. Heeney, MD, discussed results from the Solace-Kids trial, which was presented at ASH Annual Meeting and Exposition.
‘Continuous long-term education’ needed amid advances in sickle cell disease treatment
Sickle cell disease is the most common genetic disorder, affecting approximately 100,000 people in the United States.
VIDEO: Crizanlizumab may reduce hospitalization in sickle cell disease
ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.
FDA approves Adakveo to reduce pain crises from sickle cell disease
The FDA approved crizanlizumab to reduce the frequency of pain crises among people with sickle cell disease.